To investigate the correlation between vitamin D nutritional status and insulin resistance in pubertal adolescents.

To investigate body composition and associated factors in adolescents undergoing long-term regular sports training.

Objective To evaluate the clinical efficacy of a novel sleep-aid decoction in treating elderly insomnia patients with different traditional Chinese medicine (TCM) constitutional types, and its effects on neurotransmitter and inflammatory factor levels. Methods A total of 200 patients with four different TCM constitutions-peaceful, Qi-deficient, Yin-deficient, and Yang-deficient-were recruited. Peripheral blood neurotransmitter and inflammatory factor levels were measured for variations among insomnia patients across different constitutions. These patients were treated using the novel sleep-aid decoction, the effects of which were evaluated based on changes in neurotransmitters and inflammatory factors. Results Compared to the peaceful constitution group, insomnia patients with Qi-deficient, Yin-deficient, and Yang-deficient constitutions exhibited significantly elevated baseline levels of neurotransmitters (5-HT, GABA) and inflammatory factors (IL-6, TNF-α, IL-1β, CRP). Following the treatment, the Qi-deficient and Yin-deficient groups showed a marked increase in 5-HT levels, restored balance of Glu, GABA, and melatonin, and significant reductions in IL-6 and TNF-α levels. The overall effective rate was 83.5%, with optimal efficacy observed in the Qi-deficient (97.72%) and Yin-deficient (95.34%) groups. Conclusion The novel sleep-aid decoction is effective in treating insomnia in elderly patients, with the best results observed in the Qi-deficient and Yin-deficient constitution groups.
Humans ; Sleep Initiation and Maintenance Disorders/blood* ; Aged ; Male ; Female ; Drugs, Chinese Herbal/therapeutic use* ; Medicine, Chinese Traditional ; Middle Aged ; Tumor Necrosis Factor-alpha/blood* ; Sleep Aids, Pharmaceutical/therapeutic use* ; Anti-Inflammatory Agents/therapeutic use* ; Interleukin-6/blood* ; Interleukin-1beta/blood* ; Neurotransmitter Agents/blood* ; Aged, 80 and over ; C-Reactive Protein/metabolism*

Objective:To investigate the longitudinal mutual predictive relationship between college students' psychological capital and meaning in life across time.Methods:A total of 604 college students were selected for a one-year two-stage longitudinal tracking(T1 and T2),using the Psychological Capital Questionnaire for Adolescent Students(PC-QAS)and Chinese Meaning in Life Questionnaire(C-MLQ)for measurement.Results:The T1 PC-QAS scores were positively correlated with the T1 C-MLQ scores and T2 PC-QAS scores(r=0.61,0.51,Ps＜0.001).The T2 C-MLQ scores were positively correlated with the T2 PC-QAS scores and T1 C-MLQ scores(r=0.58,0.57,Ps＜0.001).The results of cross lagged regression analysis indicated that the T1 PC-QAS scores posi-tively predicted the T2 C-MLQ scores(β=0.15,P＜0.001),and T1 C-MLQ scores positively predicted T2 PC-QAS scores(β=0.19,P＜0.01).Conclusion:The psychological capital and meaning in life of college students have a certain degree of stability,and the two could predict each other.

Objective:To investigate the longitudinal mutual predictive relationship between college students' psychological capital and meaning in life across time.Methods:A total of 604 college students were selected for a one-year two-stage longitudinal tracking(T1 and T2),using the Psychological Capital Questionnaire for Adolescent Students(PC-QAS)and Chinese Meaning in Life Questionnaire(C-MLQ)for measurement.Results:The T1 PC-QAS scores were positively correlated with the T1 C-MLQ scores and T2 PC-QAS scores(r=0.61,0.51,Ps＜0.001).The T2 C-MLQ scores were positively correlated with the T2 PC-QAS scores and T1 C-MLQ scores(r=0.58,0.57,Ps＜0.001).The results of cross lagged regression analysis indicated that the T1 PC-QAS scores posi-tively predicted the T2 C-MLQ scores(β=0.15,P＜0.001),and T1 C-MLQ scores positively predicted T2 PC-QAS scores(β=0.19,P＜0.01).Conclusion:The psychological capital and meaning in life of college students have a certain degree of stability,and the two could predict each other.

Objective:To explore the relationship between trait mindfulness and nomophobia in middle school students.Methods:A total of 942 middle school students were selected to use the Mindfulness Attention Awareness Scale and the Nomophobia Scale for Chinese for two data collection intervals of 12 months(T1 and T2,respective-ly).Results:The MAAS scores were higher at T1 than at T2(P＜0.001).The simultaneous(r=-0.11,-0.21,Ps＜0.01)and sequential(r=-0.14,-0.15,Ps＜0.001)correlations between MAAS scores and NSC scores were significant.The MAAS scores at T1 negatively predicted the NSC scores at T2(β=-0.09),and the NSC scores at T1 also negatively predicted the MAAS scores at T2(β=-0.10).Conclusion:It suggests that trait mind-fulness and nomophobia could predict each other in middle school students.

Objective:To explore the relationship between trait mindfulness and nomophobia in middle school students.Methods:A total of 942 middle school students were selected to use the Mindfulness Attention Awareness Scale and the Nomophobia Scale for Chinese for two data collection intervals of 12 months(T1 and T2,respective-ly).Results:The MAAS scores were higher at T1 than at T2(P＜0.001).The simultaneous(r=-0.11,-0.21,Ps＜0.01)and sequential(r=-0.14,-0.15,Ps＜0.001)correlations between MAAS scores and NSC scores were significant.The MAAS scores at T1 negatively predicted the NSC scores at T2(β=-0.09),and the NSC scores at T1 also negatively predicted the MAAS scores at T2(β=-0.10).Conclusion:It suggests that trait mind-fulness and nomophobia could predict each other in middle school students.

Objective: The PAOLA-1 trial (NCT02477644) reported final survival benefit associated with olaparib plus bevacizumab maintenance treatment of patients with advanced ovarian cancer (AOC) based on molecular status. Our aimed to compare the cost-effectiveness of olaparib plus bevacizumab for overall patients, patients with a breast cancer susceptibility genes (BRCA) mutation, homologous recombination deficiency (HRD), or HRD without BRCA mutations AOC from the context of the American healthcare system. Methods: Analysis of health outcomes in life-years (LYs), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) in various molecular status-based AOC patient at a $150,000/QALY of willingness-to-pay was performed using a state-transitioned Markov model with a 20-year time horizon. Meanwhile, sensitivity analyses assessments were also used to gauge the model’s stability. Results: The ICERs of olaparib plus bevacizumab versus bevacizumab alone were $487,428 ($374,758), $249,579 ($191,649), $258,859 ($198,739), and $270,736 ($206,640) per QALY (LY) in the overall patients, patients with BRCA mutations, patients with HRD, and patients with HRD without BRCA mutations AOC, respectively, which indicated that The ICERs was higher than $150,000/QALY in the US. Progression-free survival (PFS) value and olaparib cost emerged as the primary influencing factors of these findings in the sensitivity analysis. Conclusion At current cost levels, olaparib plus bevacizumab treatment is not a cost-effective treatment for patients with AOC regardless of their molecular status in the US. However, this maintenance treatment may be more favorable health advantages for patients with BRAC mutations AOC.

Objective: The PAOLA-1 trial (NCT02477644) reported final survival benefit associated with olaparib plus bevacizumab maintenance treatment of patients with advanced ovarian cancer (AOC) based on molecular status. Our aimed to compare the cost-effectiveness of olaparib plus bevacizumab for overall patients, patients with a breast cancer susceptibility genes (BRCA) mutation, homologous recombination deficiency (HRD), or HRD without BRCA mutations AOC from the context of the American healthcare system. Methods: Analysis of health outcomes in life-years (LYs), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) in various molecular status-based AOC patient at a $150,000/QALY of willingness-to-pay was performed using a state-transitioned Markov model with a 20-year time horizon. Meanwhile, sensitivity analyses assessments were also used to gauge the model’s stability. Results: The ICERs of olaparib plus bevacizumab versus bevacizumab alone were $487,428 ($374,758), $249,579 ($191,649), $258,859 ($198,739), and $270,736 ($206,640) per QALY (LY) in the overall patients, patients with BRCA mutations, patients with HRD, and patients with HRD without BRCA mutations AOC, respectively, which indicated that The ICERs was higher than $150,000/QALY in the US. Progression-free survival (PFS) value and olaparib cost emerged as the primary influencing factors of these findings in the sensitivity analysis. Conclusion At current cost levels, olaparib plus bevacizumab treatment is not a cost-effective treatment for patients with AOC regardless of their molecular status in the US. However, this maintenance treatment may be more favorable health advantages for patients with BRAC mutations AOC.

Objective: The PAOLA-1 trial (NCT02477644) reported final survival benefit associated with olaparib plus bevacizumab maintenance treatment of patients with advanced ovarian cancer (AOC) based on molecular status. Our aimed to compare the cost-effectiveness of olaparib plus bevacizumab for overall patients, patients with a breast cancer susceptibility genes (BRCA) mutation, homologous recombination deficiency (HRD), or HRD without BRCA mutations AOC from the context of the American healthcare system. Methods: Analysis of health outcomes in life-years (LYs), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) in various molecular status-based AOC patient at a $150,000/QALY of willingness-to-pay was performed using a state-transitioned Markov model with a 20-year time horizon. Meanwhile, sensitivity analyses assessments were also used to gauge the model’s stability. Results: The ICERs of olaparib plus bevacizumab versus bevacizumab alone were $487,428 ($374,758), $249,579 ($191,649), $258,859 ($198,739), and $270,736 ($206,640) per QALY (LY) in the overall patients, patients with BRCA mutations, patients with HRD, and patients with HRD without BRCA mutations AOC, respectively, which indicated that The ICERs was higher than $150,000/QALY in the US. Progression-free survival (PFS) value and olaparib cost emerged as the primary influencing factors of these findings in the sensitivity analysis. Conclusion At current cost levels, olaparib plus bevacizumab treatment is not a cost-effective treatment for patients with AOC regardless of their molecular status in the US. However, this maintenance treatment may be more favorable health advantages for patients with BRAC mutations AOC.